Together with EU stakeholders and trade associations we are reimagining medicine
Welcome! As the Novartis team in Brussels, we represent our company on European level and operate as the connecting piece between corporate, EU and trade associations.
Learn more about our priorities, how we reimagine medicine, get to know our team and stay in touch with us on Twitter: @NovartisEU!
To reimagine medicine is our overarching goal, therefore we’re focusing on the pharma review, corporate sustainability due diligence and various therapeutic areas.
The General Pharmaceutical Legislation is a once-in-a-generation opportunity to refine and evolve Europe’s regulatory framework – for a better future for patients and industry.
Due diligence on human rights and environmental sustainability is strongly embedded into Novartis’ business.
At Novartis, we invest in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs.
Stands for European Federation of Pharmaceutical Industries and Associations representing biopharmaceutical industry operating in Europe. EFPIA has a direct membership of 36 national associations and 39 leading pharmaceutical companies.
Is Europe's trade body for innovative companies working in the field of pharmaceuticals and medical technologies who are active in research, development of pharmaceuticals, biotechnologies and medical devices.
The European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. They represent 78 corporate, associate members and bioregions & 15 national biotechnology associations representing over 1800 biotech SMEs.
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society.
